PCP (Phencyclidine) Effects on the Brain: NMDA Receptor Antagonism

Phencyclidine (PCP, "angel dust") is a non-competitive antagonist at the NMDA subtype of glutamate receptor (N-methyl-D-aspartate receptor).

Primary Neuropharmacology

  • Binds inside the NMDA receptor ion channel (phencyclidine binding site) → blocks cation (Ca²⁺, Na⁺) influx.
  • Disrupts glutamatergic neurotransmission → alters synaptic plasticity, learning, memory.
  • Key regions: cerebral cortex (cognition, perception), hippocampus (memory), amygdala (emotion, fear).
  • Also affects dopamine, norepinephrine, serotonin, sigma, and nicotinic receptors.

Acute Effects

  • Dissociation (detachment from self/environment), hallucinations, delirium.
  • Ataxia, nystagmus, hypertension, tachycardia.
  • Agitation, aggression, analgesia (risk of self-injury).
  • Seizures, rhabdomyolysis, hyperthermia at high doses.

Chronic Effects

  • Cognitive impairment (memory, executive function), persistent psychosis, mood disorders.
  • Structural brain changes (cortical atrophy, white matter abnormalities).

PCP's NMDA blockade underlies its unique dissociative anesthetic and psychotomimetic profile. No specific antidote; management is supportive.

Brain & Nervous System - Related Articles